FindTrial
Sign In

EGFR testing (A molecular test) in advanced Lung cancer in patients treated with radiation therapy.

EGFR Mutation status in locally advanced NSCLC patients treated with Definitive Radiotherapy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/05/008651
Enrollment
150
Registered
2017-05-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Advanced Lung cancer patients

Interventions

Intervention1: Not Applicable: Not Applicable Control Intervention1: Not Applicable: Not Applicable

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: All patients with locally advanced Non-small cell lung cancer treated with radical intent with radiotherapy or chemo-radiotherapy. All patients should have biopsy to do EGFR mutation analysis

Exclusion criteria

Exclusion criteria: Patients without an available biopsy.

Design outcomes

Primary

MeasureTime frame
1. To determine the rate of EGFR mutation in locally advanced NSCLC patients treated with radical thoracic radiation.Timepoint: 2 months after completion of Radiotherapy.—

Secondary

MeasureTime frame
1. To evaluate the effect of EGFR mutation on response rate in locally advanced NSCLC patients treated with radical thoracic radiation. 2. To evaluate the effect of EGFR mutation on progression free survival in locally advanced NSCLC patients treated with radical thoracic radiation 3. To evaluate the effect of EGFR mutation on overall survival in locally advanced NSCLC patients treated with radical thoracic radiation Timepoint: 1. On Baseline Biopsy 2. & 3. At Progression & at Death—

Countries

India

Contacts

Public ContactDr Vanita Noronha

Tata Memorial Hospital

vanita.noronha@gmail.com9769328047

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026